Windtree Therapeutics, Inc. (NasdaqCM: WINT) showcased encouraging results from the Phase 2b SEISMiC study of istaroxime, its novel investigational therapy for early cardiogenic shock, at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback